The abstract is read at the publisher; the summary is JClub's.
A plasma eMTBR-tau immunoassay shows 50.5-fold and 25.2-fold higher levels at Braak stage VI versus I–II in two US autopsy cohorts.
- Why it matters: Blood biomarkers reflecting neurofibrillary tau burden are limited, and a scalable immunoassay could enable broader research and support clinical evaluation of advanced Alzheimer-related pathology.
- What they did: In a cross-sectional design across 4 cohorts (728 total), plasma eMTBR-tau was measured by immunoassay and compared with neuropathologic Braak stages and tau-PET Braak stages, plus tau-PET SUVRs and mass spectrometry eMTBR-tau243.
- The result: In imaging cohorts, eMTBR-tau rose 11.0-fold at tau-PET Braak III–IV and 59.9-fold at V–VI versus stage 0, correlated with tau-PET SUVRs (up to 0.85), and matched mass spectrometry discrimination (AUC 0.96–0.99 vs 0.97–0.99).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.